BioCentury | Oct 8, 2007
Strategy

Opportunistic transformation

...the FBDD platform by integrating the nuclear magnetic resonance (NMR) screening assets it acquired from Combinature Biopharm AG...
...integrate SAR-by-NMR for producing high-affinity ligands from fragment molecules, to which it received access from Combinature...
BioCentury | Jun 18, 2007
Company News

Evotec, MerLion deal

...EVT acquired nuclear magnetic resonance (NMR) screening assets from MerLion's Combinature Biopharm AG subsidiary and received access to...
BioCentury | Aug 28, 2006
Strategy

The sun rises in the East

...Last week, the company announced a pair of mergers intended to fill those gaps with Combinature Biopharm AG...
...for candidate companies" to acquire, he said. "We spent 18 months and settled on Combinature." Combinature...
...formed in 2000 and its investors include 3i; Aurelia Private Equity; and BC Venture Capital. Combinature...
BioCentury | Aug 28, 2006
Company News

Athelas, Combinature, MerLion deal

...and Combinature in two stock deals. The European companies will become subsidiaries of MerLion, and Combinature...
...discovery technology and Combinature's preclinical infectious disease candidates and nuclear magnetic resonance (NMR) screening technology. Combinature's...
...complicated skin and soft tissue infections (cSSTIs) and community-acquired pneumonia (CAP) in the hospital setting. Combinature...
BioCentury | Aug 22, 2006
Company News

MerLion merges with two companies, raises $25M

...Switzerland) and Combinature (Berlin, Germany). The European companies will become subsidiaries of MerLion , and Combinature...
...DiVi discovery technology and Combinature's preclinical infectious candidates and nuclear magnetic resonance (NMR) screening technology. Combinature's...
...complicated skin and soft tissue infections (cSSTIs) and community-acquired pneumonia (CAP) in the hospital setting. Combinature...
BioCentury | Apr 11, 2005
Strategy

Combinature takes the natural path

...natural compound play Combinature Biopharm AG is moving into the product space with four preclinical compounds. When Combinature...
...AG (FSE:DGX, Frankfurt, Germany) and industrial enzymes specialist Novozymes A/S (CSE:NZYM B, Bagsvaerd, Denmark). But Combinature...
...develop and commercialize products in dermatology, while Combinature retained rights in other indications. In parallel, Combinature...
BioCentury | Jan 17, 2005
Company News

Combinature, UCB deal

...ligands that bind to an undisclosed cancer target from UCB. Financial terms were not disclosed. Combinature Biopharm AG...
BioCentury | Jul 26, 2004
Company News

Combinature, Aventis SA deal

...compound. Combinature received from AVE the preclinical data package, a production strain and GMP-produced material. Combinature Biopharm AG...
BioCentury | Dec 15, 2003
Company News

Combinature, Schering deal

...will use its combinatorial biosynthesis technology to generate derivatives of a dermatology compound from SCH. Combinature...
...and is eligible for milestones and royalties. SCH has exclusive worldwide rights to resulting compounds. Combinature Biopharm AG...
BioCentury | Dec 11, 2003
Company News

Schering, Combinature dermatology deal

...its combinatorial biosynthesis technology to generate derivatives of a dermatology compound from Schering (FSE:SCH; SHR). Combinature...
Items per page:
1 - 10 of 10
BioCentury | Oct 8, 2007
Strategy

Opportunistic transformation

...the FBDD platform by integrating the nuclear magnetic resonance (NMR) screening assets it acquired from Combinature Biopharm AG...
...integrate SAR-by-NMR for producing high-affinity ligands from fragment molecules, to which it received access from Combinature...
BioCentury | Jun 18, 2007
Company News

Evotec, MerLion deal

...EVT acquired nuclear magnetic resonance (NMR) screening assets from MerLion's Combinature Biopharm AG subsidiary and received access to...
BioCentury | Aug 28, 2006
Strategy

The sun rises in the East

...Last week, the company announced a pair of mergers intended to fill those gaps with Combinature Biopharm AG...
...for candidate companies" to acquire, he said. "We spent 18 months and settled on Combinature." Combinature...
...formed in 2000 and its investors include 3i; Aurelia Private Equity; and BC Venture Capital. Combinature...
BioCentury | Aug 28, 2006
Company News

Athelas, Combinature, MerLion deal

...and Combinature in two stock deals. The European companies will become subsidiaries of MerLion, and Combinature...
...discovery technology and Combinature's preclinical infectious disease candidates and nuclear magnetic resonance (NMR) screening technology. Combinature's...
...complicated skin and soft tissue infections (cSSTIs) and community-acquired pneumonia (CAP) in the hospital setting. Combinature...
BioCentury | Aug 22, 2006
Company News

MerLion merges with two companies, raises $25M

...Switzerland) and Combinature (Berlin, Germany). The European companies will become subsidiaries of MerLion , and Combinature...
...DiVi discovery technology and Combinature's preclinical infectious candidates and nuclear magnetic resonance (NMR) screening technology. Combinature's...
...complicated skin and soft tissue infections (cSSTIs) and community-acquired pneumonia (CAP) in the hospital setting. Combinature...
BioCentury | Apr 11, 2005
Strategy

Combinature takes the natural path

...natural compound play Combinature Biopharm AG is moving into the product space with four preclinical compounds. When Combinature...
...AG (FSE:DGX, Frankfurt, Germany) and industrial enzymes specialist Novozymes A/S (CSE:NZYM B, Bagsvaerd, Denmark). But Combinature...
...develop and commercialize products in dermatology, while Combinature retained rights in other indications. In parallel, Combinature...
BioCentury | Jan 17, 2005
Company News

Combinature, UCB deal

...ligands that bind to an undisclosed cancer target from UCB. Financial terms were not disclosed. Combinature Biopharm AG...
BioCentury | Jul 26, 2004
Company News

Combinature, Aventis SA deal

...compound. Combinature received from AVE the preclinical data package, a production strain and GMP-produced material. Combinature Biopharm AG...
BioCentury | Dec 15, 2003
Company News

Combinature, Schering deal

...will use its combinatorial biosynthesis technology to generate derivatives of a dermatology compound from SCH. Combinature...
...and is eligible for milestones and royalties. SCH has exclusive worldwide rights to resulting compounds. Combinature Biopharm AG...
BioCentury | Dec 11, 2003
Company News

Schering, Combinature dermatology deal

...its combinatorial biosynthesis technology to generate derivatives of a dermatology compound from Schering (FSE:SCH; SHR). Combinature...
Items per page:
1 - 10 of 10